Maravai LifeSciences Inc... (MRVI)
Maravai LifeSciences Statistics
Share Statistics
Maravai LifeSciences has 141.84M shares outstanding. The number of shares has increased by 7.21% in one year.
| Shares Outstanding | 141.84M |
| Shares Change (YoY) | 7.21% |
| Shares Change (QoQ) | -43.77% |
| Owned by Institutions (%) | 99.01% |
| Shares Floating | 117.88M |
| Failed to Deliver (FTD) Shares | 13 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 8.92M, so 6.29% of the outstanding shares have been sold short.
| Short Interest | 8.92M |
| Short % of Shares Out | 6.29% |
| Short % of Float | 7.57% |
| Short Ratio (days to cover) | 4.9 |
Valuation Ratios
The PE ratio is -7.26 and the forward PE ratio is -84.15. Maravai LifeSciences's PEG ratio is 0.06.
| PE Ratio | -7.26 |
| Forward PE | -84.15 |
| PS Ratio | 2.99 |
| Forward PS | 1 |
| PB Ratio | 2.07 |
| P/FCF Ratio | 14.24 |
| PEG Ratio | 0.06 |
Enterprise Valuation
Maravai LifeSciences Inc. has an Enterprise Value (EV) of 900.07M.
| EV / Earnings | -7.56 |
| EV / Sales | 3.12 |
| EV / EBITDA | 1.26 |
| EV / EBIT | -28.44 |
| EV / FCF | 14.84 |
Financial Position
The company has a current ratio of 8, with a Debt / Equity ratio of 1.47.
| Current Ratio | 8 |
| Quick Ratio | 7.41 |
| Debt / Equity | 1.47 |
| Total Debt / Capitalization | 59.45 |
| Cash Flow / Debt | 0.21 |
| Interest Coverage | -0.69 |
Financial Efficiency
Return on equity (ROE) is -0.29% and return on capital (ROIC) is 0.51%.
| Return on Equity (ROE) | -0.29% |
| Return on Assets (ROA) | -0.08% |
| Return on Capital (ROIC) | 0.51% |
| Revenue Per Employee | $498,181.03 |
| Profits Per Employee | $-205,222.41 |
| Employee Count | 580 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 2.89 |
Taxes
| Income Tax | 756.11M |
| Effective Tax Rate | 1.22 |
Stock Price Statistics
The stock price has increased by -67.85% in the last 52 weeks. The beta is 0, so Maravai LifeSciences's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | -67.85% |
| 50-Day Moving Average | 4.45 |
| 200-Day Moving Average | 6.88 |
| Relative Strength Index (RSI) | 27.53 |
| Average Volume (20 Days) | 2.79M |
Income Statement
In the last 12 months, Maravai LifeSciences had revenue of 288.94M and earned -119.03M in profits. Earnings per share was -0.9.
| Revenue | 288.94M |
| Gross Profit | 140.2M |
| Operating Income | -31.65M |
| Net Income | -119.03M |
| EBITDA | 712.41M |
| EBIT | -31.65M |
| Earnings Per Share (EPS) | -0.9 |
Balance Sheet
The company has 574.96M in cash and 610.97M in debt, giving a net cash position of -36.01M.
| Cash & Cash Equivalents | 574.96M |
| Total Debt | 610.97M |
| Net Cash | -36.01M |
| Retained Earnings | 285.74M |
| Total Assets | 1.28B |
| Working Capital | 615.86M |
Cash Flow
In the last 12 months, operating cash flow was 126.22M and capital expenditures -65.55M, giving a free cash flow of 60.67M.
| Operating Cash Flow | 126.22M |
| Capital Expenditures | -65.55M |
| Free Cash Flow | 60.67M |
| FCF Per Share | 0.46 |
Margins
Gross margin is 48.52%, with operating and profit margins of -10.95% and -41.19%.
| Gross Margin | 48.52% |
| Operating Margin | -10.95% |
| Pretax Margin | 213.79% |
| Profit Margin | -41.19% |
| EBITDA Margin | 246.56% |
| EBIT Margin | -10.95% |
| FCF Margin | 21% |
Dividends & Yields
MRVI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -35.43% |
| FCF Yield | 16.81% |
Analyst Forecast
The average price target for MRVI is $10, which is 293.7% higher than the current price. The consensus rating is "Hold".
| Price Target | $10 |
| Price Target Difference | 293.7% |
| Analyst Consensus | Hold |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 2.62 |
| Piotroski F-Score | 5 |